Mirati Therapeutics Inc
MRTX.O- Latest Trade
- trading higher40.5USD
- 0
- 0.00%
- As of Jun 7 2023. Values delayed up to 15 minutes
- Today's Range
- -- - --
- 52 Week Range
- 35.70 - 101.30
- Previous Close
- 40.50
- Open
- 0.00
- Volume
- 0.00
- 3 Month Average Trading Volume
- 21.94
- Shares Out (Mil)
- 58.19
- Market Cap
- 2,293.14
- Forward P/E
- -3.22
- Dividend Yield
- 0.00
Key Statistics
2.12 mean rating - 17 analysts
- P/E Excl. Extra Items (TTM)
- 0.00
- Price To Sales (TTM)
- 121.37
- Price To Book (Quarterly)
- 2.66
- Price To Cash Flow (Per Share TTM)
- 0.00
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -66.80
- Return On Equity (TTM)
- -60.04
2021 (millions USD)
About Mirati Therapeutics Inc (MRTX.O)
Company Information
Mirati Therapeutics, Inc. is a commercial-stage oncology company. The Company is developing novel therapeutics to address the genetic and immunological promoters of cancer. The Company's product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.
Address
3545 Cray CourtSAN DIEGO, CA
92121
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Faheem Hasnain
- Lead Independent Chairman of the Board
- Charles M. Baum
- President, Founder, Director, Head - Research and Development
- David Meek
- Chief Executive Officer, Director
- Laurie D. Stelzer
- Chief Financial Officer
- James G. Christensen
- Chief Scientific Officer
- Benjamin J. Hickey
- Chief Commercial Officer
- Alan Sandler
- Chief Medical Officer
- John B. Moriarty
- Chief Legal Officer, Corporate Secretary
- Bruce L. A. Carter
- Independent Director
- Julie M. Cherrington
- Independent Director
- Aaron I. Davis
- Independent Director
- Craig A. Johnson
- Independent Director
- Maya Martinez-Davis
- Independent Director
- Shalini Sharp
- Independent Director
Latest News
- BusinessMirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
Early trial data shows that a combination of Mirati Therapeutics experimental drug adagrasib and Merck & Co's immunotherapy Keytruda helped about half of previously untreated metastatic lung cancer patients, with manageable side effects, Mirati said on Monday.
- MarketsMirati attracts fresh takeover interest - Bloomberg News
Mirati Therapeutics Inc is attracting fresh takeover interest from large pharmaceutical companies ahead of updates to its drug pipeline, Bloomberg News reported on Tuesday, citing people with knowledge of the matter.
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,955.90 | 0.49% |
| Copper | 722.50 | 0.01% |
| Brent Crude Oil | 76.86 | 0.75% |
| CBOT Soybeans | 1,360.00 | 0.50% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,279.35 | 0.11% |
| Euro STOXX 50 | 4,288.58 | 0.15% |
| FTSE 100 | 7,618.47 | 0.13% |
| Nikkei 225 | 31,913.74 | 1.82% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes